Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitorSuyoun Chung(OncoTherapy Science (Japan)), Yusuke Nakamura(University of Chicago)OncotargetFebruary 24, 201610.18632/oncotarget.7685Cited by 37SaveCiteExport RISWatch citationsRelated PapersSomatic mutations of the <i>APC</i> gene in colorectal tumors: mutation cluster region in the <i>APC</i> gene|Human Molecular Genetics|1992|934Critical roles of SMYD2-mediated β-catenin methylation for nuclear translocation and activation of Wnt signaling|Oncotarget|2017|43MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells|Oncology Reports|2019|21